Abstract
Selective blockade of hypoxia-inducible gene expression by designed small molecules would prove valuable in suppressing tumor angiogenesis, metastasis and altered energy metabolism. We report the design, synthesis, and biological evaluation of a dimeric epidithiodiketopiperazine (ETP) small molecule transcriptional antagonist targeting the interaction of the p300/CBP coactivator with the transcription factor HIF-1R. Our results indicate that disrupting this interaction results in rapid downregulation of hypoxiainducible genes critical for cancer progression. The observed effects are compound-specific and dosedependent. Controlling gene expression with designed small molecules targeting the transcription factorcoactivator interface may represent a new approach for arresting tumor growth.
Original language | English (US) |
---|---|
Pages (from-to) | 18078-18088 |
Number of pages | 11 |
Journal | Journal of the American Chemical Society |
Volume | 131 |
Issue number | 50 |
DOIs | |
State | Published - Dec 23 2009 |
ASJC Scopus subject areas
- Catalysis
- General Chemistry
- Biochemistry
- Colloid and Surface Chemistry